OliX Pharmaceuticals, Inc (KOSDAQ:226950)

Market Cap	864.18B
Revenue (ttm)	5.68B
Net Income (ttm)	-40.66B
Shares Out	19.78M
EPS (ttm)	-2,414.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	385,210
Average Volume	591,177
Open	43,500
Previous Close	42,800
Day's Range	42,500 - 45,450
52-Week Range	8,280 - 64,000
Beta	0.81
RSI	43.81
Earnings Date	May 14, 2025

About OliX Pharmaceuticals

OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company’s products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepatitis; and OLX301D for subretinal fibrosis. The company has a license and collaboration agreement with Hansoh Pharmaceuticals; development collaboration ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 226950

Financial Performance

In 2024, OliX Pharmaceuticals's revenue was 5.68 billion, a decrease of -66.73% compared to the previous year's 17.06 billion. Losses were -40.66 billion, 112.9% more than in 2023.